Plasmodium vivax chloroquine resistance and anemia in the western brazilian amazon

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 1, 2014, Pages 342-347

  Marques, Marly M ^a,b   Costa, Monica R F ^a   Santana Filho, Franklin S ^a,b   Vieira, José L F ^c   Nascimento, Margareth T S ^c   Brasil, Larissa W ^b   Nogueira, Fátima ^d   Silveira, Henrique ^d   Reyes Lecca, Roberto C ^a   Monteiro, Wuelton M ^a,b   Lacerda, Marcus V G ^a,b   Alecrim, Maria G C ^a,b  

^a Fundacao de Medicina Tropical Dr Heitor Vieira Dourado   (Brazil)

^b UNIVERSIDADE DO ESTADO DO AMAZONAS   (Brazil)

^c FEDERAL UNIVERSITY OF PARÁ   (Brazil)

^d INSTITUTO DE HIGIENE E MEDICINA TROPICAL   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE; DEETHYLCHLOROQUINE; HEMOGLOBIN; PRIMAQUINE;

ADULT; ANEMIA; ARTICLE; BRAZIL; DRUG BLOOD LEVEL; DRUG RESISTANCE; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; GENE MUTATION; GENE SEQUENCE; HEMOGLOBIN BLOOD LEVEL; HUMAN; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; PARASITEMIA; PLASMODIUM VIVAX; PLASMODIUM VIVAX MALARIA; PRIORITY JOURNAL;

ANEMIA; ANTIMALARIALS; BRAZIL; CHLOROQUINE; DRUG RESISTANCE; FEMALE; HUMANS; MALARIA, VIVAX; MALE; PLASMODIUM VIVAX;

EID: 84891503502     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02279-12     Document Type: Article

References (45)

1. Mueller I, Galinski MR, Baird JK, Carlton JM, Kochar DK, Alonso PL, del Portillo HA. 2009. Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite. Lancet Infect. Dis. 9:555-566. http://dx.doi.org/10. 1016/S1473-3099(09)70177-X.
2. WHO. 2012. World malaria report 2012. WHO, Geneva, Switzerland.
3. Most H, London IM, et al. 1946. Chloroquine for treatment of acute attacks of vivax malaria. JAMA 131:963-967. http://dx.doi.org/10.1001/jama.1946. 02870290013005.
4. McChesney EW, Fasco MJ, Banks WF, Jr. 1967. The metabolism of chloroquine in man during and after repeated oral dosage. J. Pharmacol. Exp. Ther. 158:323-331.
5. Coatney GR, Ruhe DS, et al. 1949. Studies in human malaria; the protective and therapeutic action of chloroquine (SN 7618) against St. Elizabeth strain vivax malaria. Am. J. Hyg. (Lond.) 49:49-59.
6. Baird JK. 2004. Chloroquine resistance in Plasmodium vivax. Antimicrob. Agents Chemother. 48:4075-4083. http://dx.doi.org/10.1128/AAC.48.11.4075-4083. 2004.
7. Rieckmann KH, Davis DR, Hutton DC. 1989. Plasmodium vivax resistance to chloroquine? Lancet ii:1183-1184.
8. Phillips EJ, Keystone JS, Kain KC. 1996. Failure of combined chloroquine and high-dose primaquine therapy for Plasmodium vivax malariaacquired in Guyana, South America. Clin. Infect. Dis. 23:1171-1173. http://dx.doi.org/10.1093/ clinids/23.5.1171.
9. Baird JK, Tiwari T, Martin GJ, Tamminga CL, Prout TM, Tjaden J, Bravet PP, Rawlins S, Ferrel M, Carucci D, Hoffman SL. 2002. Chloroquine for the treatment of uncomplicated malaria in Guyana. Ann. Trop. Med. Parasitol. 96:339-348. http://dx.doi.org/10.1179/000349802125001023.
10. Castillo CM, Osorio LE, Palma GI. 2002. Assessment of therapeutic response of Plasmodium vivax and Plasmodium falciparum to chloroquine in a malaria transmission free area in Colombia. Mem. Inst. Oswaldo Cruz 97:559-562. http://dx.doi.org/10.1590/S0074-02762002000400020.
11. Villalobos-Salcedo JM, Tada MS, Kimura E, Menezes MJ, Pereira da Silva LH. 2000. In-vivo sensitivity of Plasmodium vivax isolates from Rondônia (western Amazon region, Brazil) to regimens including chloroquine and primaquine. Ann. Trop. Med. Parasitol. 94:749-758. http://dx.doi.org/10.1080/ 00034980020027960.
12. Machado RL, de Figuereido Filho AF, Calvosa VS, Figueredo MC, Nascimento JM, Povoa MM. 2003. Correlation between Plasmodium vivax variants in Belém, Para State, Brazil and symptoms and clearance of parasitemia. Braz J. Infect. Dis. 7:175-177. http://dx.doi.org/10.1590/S1413-86702003000300002
13. Alecrim MG, Alecrim W, Macedo V. 1999. Plasmodium vivax resistance to chloroquine (R2) and mefloquine (R3) in Brazilian Amazon region. Rev. Soc. Bras. Med. Trop. 32:67-68.
14. Soto J, Toledo J, Gutierrez P, Luzz M, Llinas N, Cedeno N, Dunne M, Berman J. 2001. Plasmodium vivax clinically resistant to chloroquine in Colombia. Am. J. Trop. Med. Hyg. 65:90-93.
15. Ruebush TK, II, Zegarra J, Cairo J, Andersen EM, Green M, Pillai DR, Marquino W, Huilca M, Arevalo E, Garcia C, Solary L, Kain KC. 2003. Chloroquine-resistant Plasmodium vivax malaria in Peru. Am. J. Trop. Med. Hyg. 69:548-552.
16. Santana Filho FS, Arcanjo AR, Chehuan YM, Costa MR, Martinez- Espinosa FE, Vieira JL, Barbosa MG, Alecrim WD, Alecrim MG. 2007. Chloroquine-resistant Plasmodium vivax, Brazilian Amazon. Emerg. Infect. Dis. 13:1125-1126. http://dx.doi.org/10.3201/eid1307.061386.
17. Pukrittayakamee S, Imwong M, Looareesuwan S, White NJ. 2004. Therapeutic responses to antimalarial and antibacterial drugs in vivax malaria. Acta Trop. 89:351-356. http://dx.doi.org/10.1016/j.actatropica.2003.10.012.
18. Bray PG, Martin RE, Tilley L, Ward SA, Kirk K, Fidock DA. 2005. Defining the role of PfCRT in Plasmodium falciparum chloroquine resistance. Mol. Microbiol. 56:323-333. http://dx.doi.org/10.1111/j.1365-2958.2005.04556.x.
19. Naing C, Aung K, Win DK, Wah MJ. 2010. Efficacy and safety of chloroquine for treatment in patients with uncomplicated Plasmodium vivax infections in endemic countries. Trans. R. Soc. Trop. Med. Hyg. 104:695-705. http://dx.doi.org/10.1016/j.trstmh.2010.08.009.
20. Tjitra E, Anstey NM, Sugiarto P, Warikar N, Kenangalem E, Karyana M, Lampah DA, Price RN. 2008. Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia. PLoS Med. 5:e128. http://dx.doi.org/10.1371/journal.pmed.0050128.
21. Snounou G, Viriyakosol S, Jarra W, Thaithong S, Brown KN. 1993. Identification of the four human malaria parasite species in field samples by the polymerase chain reaction and detection of a high prevalence of mixed infections. Mol. Biochem. Parasitol. 58:283-292. http://dx.doi.org/10.1016/0166- 6851(93)90050-8.
22. World Health Organization. 2006. Guidelines for the treatment of malaria. World Health Organization, Geneva, Switzerland.
23. Dua VK, Kar PK, Gupta NC, Sharma VP. 1999. Determination of chloroquine and desethylchloroquine in plasma and blood cells of Plasmodium vivax malaria cases using liquid chromatography. J. Pharm. Biomed. Anal. 21:199-205. http://dx.doi.org/10.1016/S0731-7085(99)00097-7.
24. Patchen LC, Mount DL, Schwartz IK, Churchill FC. 1983. Analysis of filter-paper-absorbed, finger-stick blood samples for chloroquine and its major metabolite using high-performance liquid chromatography with fluorescence detection. J. Chromatogr. 278:81-89.
25. Phyo AP, Lwin KM, Price RN, Ashley EA, Russell B, Sriprawat K, Lindegardh N, Singhasivanon P, White NJ, Nosten F. 2011. Dihydroartemisinin- piperaquine versus chloroquine in the treatment of Plasmodium vivax malaria in Thailand: a randomized controlled trial. Clin. Infect. Dis. 53:977-984. http://dx.doi.org/ 10.1093/cid/cir631.
26. Awab GR, Pukrittayakamee S, Imwong M, Dondorp AM, Woodrow CJ, Lee SJ, Day NP, Singhasivanon P, White NJ, Kaker F. 2010. Dihydroartemisinin- piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority trial. Malar. J. 9:105. http://dx.doi.org/10.1186/1475-2875-9- 105.
27. Sowunmi A, Adewoye EO, Gbotsho GO, Happi CT, Sijuade A, Folarin OA, Okuboyejo TM, Michael OS. 2010. Factors contributing to delay in parasite clearance in uncomplicated falciparum malaria in children. Malar. J. 9:53. http://dx.doi.org/10.1186/1475-2875-9-53.
28. Hess FI, Iannuzzi A, Leafasia J, Cowdrey D, Nothdurft HD, Von Sonnenburg F, Loscher T, Rieckmann KH. 1996. Risk factors of chloroquine resistance in Plasmodium falciparum malaria. Acta Trop. 61:293- 306. http://dx.doi.org/10. 1016/0001-706X(96)00011-3.
29. Reilly HB, Wang H, Steuter JA, Marx AM, Ferdig MT. 2007. Quantitative dissection of clone-specific growth rates in cultured malaria parasites. Int. J. Parasitol. 37:1599-1607. http://dx.doi.org/10.1016/j.ijpara.2007.05.003.
30. Russell B, Chalfein F, Prasetyorini B, Kenangalem E, Piera K, Suwanarusk R, Brockman A, Prayoga P, Sugiarto P, Cheng Q, Tjitra E, Anstey NM, Price RN. 2008. Determinants of in vitro drug susceptibility testing of Plasmodium vivax. Antimicrob. Agents Chemother. 52:1040-1045. http://dx.doi.org/10.1128/AAC.01334- 07.
31. Ru YX, Mao BY, Zhang FK, Pang TX, Zhao SX, Liu JH, Wickramasinghe SN. 2009. Invasion of erythroblasts by Pasmodium vivax: a new mechanism contributing to malarial anemia. Ultrastruct. Pathol. 33:236- 242. http://dx.doi.org/10. 3109/01913120903251643.
32. Price RN, Douglas NM, Anstey NM. 2009. New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance. Curr. Opin. Infect. Dis. 22:430-435. http://dx.doi.org/10.1097/QCO.0b013e32832f14c1.
33. Chotivanich K, Udomsangpetch R, Simpson JA, Newton P, Pukrittayakamee S, Looareesuwan S, White NJ. 2000. Parasite multiplication potential and the severity of falciparum malaria. J. Infect. Dis. 181:1206-1209. http://dx.doi.org/10.1086/315353.
34. Fernandez-Becerra C, Pinazo MJ, Gonzalez A, Alonso PL, del Portillo HA, Gascon J. 2009. Increased expression levels of the pvcrt-o and pvmdr1 genes in a patient with severe Plasmodium vivax malaria. Malar. J. 8:55. http://dx.doi.org/10.1186/1475-2875-8-55.
35. Sa JM, Nomura T, Neves J, Baird JK, Wellems TE, del Portillo HA. 2005. Plasmodium vivax: allele variants of the mdr1 gene do not associate with chloroquine resistance among isolates from Brazil, Papua, and monkey- adapted strains. Exp. Parasitol. 109:256-259. http://dx.doi.org/10.1016/j.exppara.2004. 12.005.
36. Orjuela-Sanchez P, Santana Filho FS, Machado-Lima A, Chehuan YF, Costa MR, Alecrim MG, del Portillo HA. 2009. Analysis of singlenucleotide polymorphisms in the crt-o and mdr1 genes of Plasmodiumvivax among chloroquine-resistant isolates from the Brazilian Amazon region. Antimicrob. Agents Chemother. 53:3561-3564. http://dx.doi.org/10.1128/AAC.00004-09.
37. Gething PW, Elyazar IR, Moyes CL, Smith DL, Battle KE, Guerra CA, Patil AP, Tatem AJ, Howes RE, Myers MF, George DB, Horby P, Wertheim HF, Price RN, Mueller I, Baird JK, Hay SI. 2012. A long neglected world malaria map: Plasmodium vivax endemicity in 2010. PLoS Negl. Trop. Dis. 6:e1814. http://dx.doi.org/10.1371/journal.pntd.0001814.
38. Alexandre MA, Ferreira CO, Siqueira AM, Magalhaes BL, Mourao MP, Lacerda MV, Alecrim M. 2010. Severe Plasmodium vivax malaria, Brazilian Amazon. Emerg. Infect. Dis. 16:1611-1614. http://dx.doi.org/10.3201/eid1610.100685.
39. Lacerda MV, Fragoso SC, Alecrim MG, Alexandre MA, Magalhaes BM, Siqueira AM, Ferreira LC, Araujo JR, Mourao MP, Ferrer M, Castillo P, Martin-Jaular L, Fernandez-Becerra C, Del Portillo H, Ordi J, Alonso PL, Bassat Q. 2012. Postmortem characterization of patients with clinical diagnosis of Plasmodium vivax malaria: to what extent does this parasite kill? Clin. Infect. Dis. 55:e67-74. http://dx.doi.org/10.1093/cid/cis615.
40. Douglas NM, Anstey NM, Buffet PA, Poespoprodjo JR, Yeo TW, White NJ, Price RN. 2012. The anaemia of Plasmodium vivax malaria. Malar. J. 11:135. http://dx.doi.org/10.1186/1475-2875-11-135.
41. Marin-Menendez A, Bardaji A, Martinez-Espinosa FE, Botto-Menezes C, Lacerda MV, Ortiz J, Cistero P, Piqueras M, Felger I, Mueller I, Ordi J, del Portillo H, Menendez C, Wahlgren M, Mayor A. 2013. Rosetting in Plasmodium vivax: a cytoadhesion phenotype associated with anaemia. PLoS Negl. Trop. Dis. 7:e2155. http://dx.doi.org/10.1371/journal.pntd.0002155.
42. Barnadas C, Musset L, Legrand E, Tichit M, Briolant S, Fusai T, Rogier C, Bouchier C, Picot S, Menard D. 2009. High prevalence and fixation of Plasmodium vivax dhfr/dhps mutations related to sulfadoxine/pyrimethamine resistance in French Guiana. Am. J. Trop. Med. Hyg. 81: 19-22.
43. Hawkins VN, Joshi H, Rungsihirunrat K, Na-Bangchang K, Sibley CH. 2007. Antifolates can have a role in the treatment of Plasmodium vivax. Trends Parasitol. 23:213-222. http://dx.doi.org/10.1016/j.pt.2007.03.002.
44. Raj DK, Mu J, Jiang H, Kabat J, Singh S, Sullivan M, Fay MP, McCutchan TF, Su XZ. 2009. Disruption of a Plasmodium falciparum multidrug resistance-associated protein (PfMRP) alters its fitness and transport of antimalarial drugs and glutathione. J. Biol. Chem. 284:7687- 7696. http://dx.doi.org/10.1074/jbc.M806944200.
45. Barnadas C, Ratsimbasoa A, Tichit M, Bouchier C, Jahevitra M, Picot S, Menard D. 2008. Plasmodium vivax resistance to chloroquine in Madagascar: clinical efficacy and polymorphisms in pvmdr1 and pvcrt-o genes. Antimicrob. Agents Chemother. 52:4233-4240. http://dx.doi.org/10.1128/AAC.00578-08.